Smoking and Cardiovascular Diseases

Abstract

Abstract

Cardiovascular diseases are the foremost cause of morbidity and mortality in the world and in our country. What is favorable in terms of epidemic cardiovascular diseases is that they are substantially "preventable". Smoking is one of the leading preventable risk factors. Smoking causes development and progression of cardiovascular diseases through different pathophysiological processes such as endothelial dysfunction, development and progression of atherosclerosis, hemodynamic effects, inflammation, hypercoagulable state, and dyslipidemia. Cardiologists, who encounter the clinical consequences of smoking, play a central role in informing patients regarding the hazards of smoking, supporting them for smoking cessation, providing psychological and pharmacological treatments as well as cardiovascular effects of these treatments. Starting the fight against smoking, which seriously threatens public health, seems to be the most appropriate start regarding fight for the prevention and control of cardiovascular diseases. 

Keywords

• Tobacco and Cigarette smoking,Cardiovascular effects

References

1. Anonymous 2016a: sbu.saglik.gov.tr/Ekutuphane/kitaplar/t14.pdf. Türkiye Kalp ve Damar Hastalıklarını Önleme ve Kontrol Programı 2015-2020, Basım 2015 Ankara. (Erişim tarihi: 21.12.2016)
2. Anonymous 2016b: http://apps.who.int/iris/bitstream/10665/148114/1/9789241564854_eng. WHO, Global Status Report on Noncommunicable Diseases 2014. (Erişim tarihi: 21.12.2016)
3. Anonymous 2016c: http://whqlibdoc.who.int/publications/2011/9789241564373_eng. World Health Organization, Global Atlas on Cardiovascular Disease Prevention and Control 2011, World Heart Federation and World Stroke Organization. (Erişim tarihi: 21.12.2016)
4. Anonymous 2016d: http://whqlibdoc. who.int/publications/2012/9789241564434_eng.pdf. WHO Global Report: Mortality Attributable to Tobacco. World Health Organisation, 2012. (Erişim tarihi: 21.12.2016)
5. Anonymous 2016e: http://www.who.int/healthinfo/globalburdendisease. WHO, Global Health Risks: Mortality and burden of disease attributable to selected major risks. World Health Organization, 2009. (Erişim tarihi: 21.12.2016)
6. Anonymous 2016f: http://healthliteracy.worlded. org/docs/tobacco/Unit1/2history_of.html. From the First to the Last Ash: The History, Economics, and Hazards of Tobacco [online curriculum]. (Erişim tarihi: 22.12.2016)
7. Behr J. and Nowak, D. Tobacco smoke and respiratory disease. 161-179. 2002. ERS Journals Ltd. European Respiratory Monograph.
8. Benowitz NL. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis 2003;46:91–111.

9. Bermudez EA, Rifai N, Buring JE, Manson JE, Ridker PM. Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol, 2002;89:1117-9.
10. Canoy D, Wareham N, Luben R, et al. Cigarette smoking and fat distribution in 21,828 British men and women: a population-based study. Obes Res 2005;13:1466–75.
11. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data. BMJ 1989;298:784–8.
12. D’Alessandro A, Boeckelmann I, Hammwhoner M, Goette A. Nicotine, cigarette smoking and cardiac arrhythmia: an overview. Eur J Prev Cardiol 2012;19: 297–305.
13. Erhardt L. Cigarette smoking: an undertreated risk factor for cardiovascular disease. Atherosclerosis, 2009 Jul; 205(1):23-32.
14. Jamal A, Dube SR, Malarcher AM, Shaw L, Engstrom MC. Tobacco use screening and
15. counseling during physician office visits among adults–National Ambulatory Medical
16. Care Survey and National Health Interview Survey, United States, 2005–2009.
17. MMWR Morb Mortal Wkly Rep 2012;61(Suppl):38–45.
18. Jha P, Ramasundarahettige C, Landsman V, Rostron B, Thun M, Anderson RN,
19. McAfee T, Peto R. 21st-century hazards of smoking and benefits of cessation in
20. the United States. N Engl J Med 2013;368: 341–350.
21. Mazzone A, Cusa C, Mazzucchelli I, et al. Cigarette smoking and hypertension influence nitric oxide release and plasma levels of adhesion molecules. Clin Chem Lab Med 2001;39: 822–6.
22. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis, 2016 Sep;252: 207-74.
23. Rigotti NA, Clair C. Managing tobacco use: the neglected cardiovascular disease risk factor. Eur Heart J. 2013 Nov;34(42):3259-67.
24. Salahuddin S, Prabhakaran D, Roy A. Pathophysiological Mechanisms of Tobacco-Related CVD. Glob Heart. 2012 Jul; 7(2):113-20.
25. Smith CJ, Fischer TH. Particulate and vapor phase constituents of cigarette mainstream smoke and risk of myocardial infarction. Atherosclerosis 2001;158:257–67.
26. Tahtinen TM, Vanhala MJ, Oikarinen JA, Keinanen-Kiukaanniema SM. Effect of smoking on the prevalence of insulin resistance-associated cardiovascular risk factors among Finnish men in military service. J Cardiovasc Risk 1998;5:319–23.
27. T.C. Sağlık Bakanlığı, Küresel Yetişkin Tütün Araştırması (KYTA) - 2012, Yönetici Özeti: Türkiye.
28. Türkiye İstatistik Kurumu, Ölüm Nedeni İstatistikleri, 2015 http://www.tuik.gov.tr/
29. Haber Bulteni.doi=21526.
30. Yetkin Y. Fizyolojik çevrenin korunması ve sigara içimi ile tütün üretimi ve biyoloji eğitimi
31. arasındaki ilişki. SBAD 1992; 3: 99-110.